Showing results (151-160 of 193) with videos related to
Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|June 15, 2017
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patientsJürgen Burhenne, Lu Liu, Christoph E Heilig, et al.Frontiers in Pharmacology|April 24, 2023
Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteersVanessa Zhu, Jürgen Burhenne, Johanna Weiss, et al.Journal of Hepatology|May 2, 2016
First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex BAntje Blank, Christoph Markert, Nicolas Hohmann, et al.International Journal of Clinical Pharmacology and Therapeutics|January 30, 2014
Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentanChristoph Markert, Prisca Ngui, Regina Hellwig, et al.Cancers|June 2, 2021
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical GroupsAnna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, et al.Clinical Pharmacokinetics|October 30, 2024
Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical InsightsAyatallah Saleh, Josefine Schulz, Jan-Frederik Schlender, et al.European Journal of Drug Metabolism and Pharmacokinetics|December 20, 2023
Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy VolunteersFelicitas Stoll, Antje Blank, Gerd Mikus, et al.Pharmaceuticals (Basel, Switzerland)|February 6, 2021
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing StrategiesAnna Mueller-Schoell, Lena Klopp-Schulze, Robin Michelet, et al.Clinical Pharmacology and Therapeutics|March 8, 2022
Vericiguat in Combination with Short-Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE StudyMichael Boettcher, Hans-Dirk Düngen, Frank Donath, et al.Frontiers in Pharmacology|April 28, 2025
Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteersAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.Pageof 20